Oxford BioTherapeutics
  • ABOUT
    • OUR TEAM
    • BOARD OF DIRECTORS
    • INVESTORS
    • OFFICES & LABS
  • PIPELINES
    • INTERNAL PROGRAMS
    • PARTNERED PROGRAMS
  • PARTNERSHIPS
  • OUR SCIENCE
    • IO DISCOVERY PLATFORM >
      • IMMUNE CHECKPOINT TARGETS
      • IO ANTIBODY ENGINEERING
    • OGAP DISCOVERY PLATFORM
  • CAREERS
  • NEWS
    • PRESS RELEASES
  • CONTACT

Partnerships

Boehringer Ingelheim

OBT and Boehringer Ingelheim (BI) have been collaborating since 2013. Our initial collaboration yielded two partnered clinical products and based on this success we entered into a second collaboration in Q4 2020. Our 2020 collaboration has already yielded a program for which BI has exercised an exclusive option.

Kite Pharma

Through this collaboration, OBT will validate up to five novel oncology drug targets, previous identified using OBT's OGAP® discovery platform, and generate antibodies against them. Kite, a Gilead Company, will have the exclusive right to develop and commercialize therapies based on these targets and antibodies. 
​

Privacy Policy

Legal Notice

Site Map

© 2017 Oxford BioTherapeutics All Rights Reserved
  • ABOUT
    • OUR TEAM
    • BOARD OF DIRECTORS
    • INVESTORS
    • OFFICES & LABS
  • PIPELINES
    • INTERNAL PROGRAMS
    • PARTNERED PROGRAMS
  • PARTNERSHIPS
  • OUR SCIENCE
    • IO DISCOVERY PLATFORM >
      • IMMUNE CHECKPOINT TARGETS
      • IO ANTIBODY ENGINEERING
    • OGAP DISCOVERY PLATFORM
  • CAREERS
  • NEWS
    • PRESS RELEASES
  • CONTACT